IL315890A - Treatment of mental disorders - Google Patents

Treatment of mental disorders

Info

Publication number
IL315890A
IL315890A IL315890A IL31589024A IL315890A IL 315890 A IL315890 A IL 315890A IL 315890 A IL315890 A IL 315890A IL 31589024 A IL31589024 A IL 31589024A IL 315890 A IL315890 A IL 315890A
Authority
IL
Israel
Prior art keywords
treatment
mental disorders
mental
disorders
Prior art date
Application number
IL315890A
Other languages
English (en)
Hebrew (he)
Inventor
Theis Terwey
Conor Burke
Naoise Gaffney
Original Assignee
Gh Res Ireland Limited
Theis Terwey
Conor Burke
Naoise Gaffney
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gh Res Ireland Limited, Theis Terwey, Conor Burke, Naoise Gaffney filed Critical Gh Res Ireland Limited
Priority claimed from PCT/EP2023/057883 external-priority patent/WO2023186835A1/en
Publication of IL315890A publication Critical patent/IL315890A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16—Tryptamines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL315890A 2022-03-27 2023-03-27 Treatment of mental disorders IL315890A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP22000086 2022-03-27
EP22000083 2022-03-27
EP23153995 2023-01-30
EP23153939 2023-01-30
PCT/EP2023/057883 WO2023186835A1 (en) 2022-03-27 2023-03-27 Treatment of mental disorders

Publications (1)

Publication Number Publication Date
IL315890A true IL315890A (en) 2024-11-01

Family

ID=93292079

Family Applications (1)

Application Number Title Priority Date Filing Date
IL315890A IL315890A (en) 2022-03-27 2023-03-27 Treatment of mental disorders

Country Status (7)

Country Link
US (1) US20250241894A1 (cg-RX-API-DMAC7.html)
EP (1) EP4499086A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025510911A (cg-RX-API-DMAC7.html)
KR (1) KR20250005172A (cg-RX-API-DMAC7.html)
AU (1) AU2023246680A1 (cg-RX-API-DMAC7.html)
CA (1) CA3255635A1 (cg-RX-API-DMAC7.html)
IL (1) IL315890A (cg-RX-API-DMAC7.html)

Also Published As

Publication number Publication date
US20250241894A1 (en) 2025-07-31
EP4499086A1 (en) 2025-02-05
CA3255635A1 (en) 2023-10-05
JP2025510911A (ja) 2025-04-15
KR20250005172A (ko) 2025-01-09
AU2023246680A1 (en) 2024-11-07

Similar Documents

Publication Publication Date Title
ZA202212876B (en) 4-oxo-3,4-dihydroquinazolinon compounds for the treatment of braf-associated diseases and disorders
IL309317A (en) Treatment of diseases and disorders associated with MTRES1
IL287280A (en) Compounds and methods for the treatment of ocular disorders
GB2605422B (en) Treatment of the central nervous system
IL313920A (en) Treatment of heart and lung disorders
IL287264A (en) Compounds and methods for the treatment of ocular disorders
EP4090420A4 (en) PHOTOTHERAPEUTIC TREATMENT OF SKIN DISEASES
IL304628A (en) Treatment of skin disorders
EP4355355A4 (en) TREATMENT OF PLIN1-ASSOCIATED DISEASES AND DISORDERS
IL319571A (en) R-Trihexyphenidyl for the treatment of movement disorders
EP4232458A4 (en) COMPOUNDS AND METHODS FOR THE TREATMENT OF OCULAR DISEASES
GB2618915B (en) Treatment of cardiovascular disease
IL321120A (en) Treatment of mtres1-related diseases and disorders
GB202001353D0 (en) Treatment of skin conditions
IL327357A (en) Combined treatment method for autoimmune disorders
IL317599A (en) Device for treating eye disorders
LT4313114T (lt) Kombinuotas smegenų traumos gydymas
GB202007054D0 (en) Treatment of lipid disorders
CA3287339A1 (en) Advantageous fluorobenzofurans for the treatment of mental disorders or enhancement
GB201904717D0 (en) Treatment and diagnosis of mental disorders
CA3282838A1 (en) Piperazine-substituted benzothiophenes for treatment of mental disorders
IL315909A (en) Gene therapy for the treatment of cognitive disorders
GB202416895D0 (en) Treatment of sleep disorders
GB202104753D0 (en) Treatment of ophthalmological conditions
HK40104631A (en) Treatment of skin disorders